Assessment of DNA Damage Induced by Velum® Prime in Human Lymphocytes


Toğay V. A., Çelik D.

JOURNAL OF CONTEMPORARY MEDICINE, cilt.13, sa.5, ss.824-829, 2023 (Hakemli Dergi)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 13 Sayı: 5
  • Basım Tarihi: 2023
  • Doi Numarası: 10.16899/jcm.1345215
  • Dergi Adı: JOURNAL OF CONTEMPORARY MEDICINE
  • Derginin Tarandığı İndeksler: Directory of Open Access Journals
  • Sayfa Sayıları: ss.824-829
  • Süleyman Demirel Üniversitesi Adresli: Evet

Özet

Aim: Fluopyram is a mitochondrial complex II inhibitor with low water solubility and a relatively long half-life in soil. So it may also be dangerous for humans. The effect of fluopyram on DNA damage was evaluated in human lymphocytes using the comet assay.
Materials and Methods: Lymphocytes of eight volunteers were isolated using histopaque-1077. Fluopyram was administered at doses of 0.05, 0.25, and 1.00 mg/mL for 1, 2, and 4 h. The comet assay was applied, and photographs of the slides were taken under a fluorescence microscope. 50 cells per slide were analyzed using the OpenComet software. The obtained results were statistically evaluated using one-way ANOVA.
Results: Fluopyram treatments at 1.00 mg/mL for 1 h and 0.05, 0.25, and 1.00 mg/mL for 2 and 4 h resulted in a statistically significant increase in DNA damage compared to the internal control groups (p<0.05). When comparing groups with the same treatment time but different doses, the increase in DNA damage observed after a 1-h treatment of 1.00 mg/mL fluopyram was higher than the increase observed after a 1-h treatment of 0.05 mg/mL fluopyram (p<0.05). When comparing groups with different treatment times but the same dose, the increase in DNA damage after a 4-h treatment of 0.25 mg/mL fluopyram was higher than the increase observed after a 1-h treatment of 0.25 mg/mL fluopyram (p<0.05).
Conclusions: The results suggest that fluopyram causes an increase in DNA damage in a dose- and time-dependent manner. It is essential to investigate these findings in vivo as well.